Bio-Gene Technology (ASX:BGT) Gross Profit: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Gene Technology Gross Profit?

Bio-Gene Technology ASX:BGT +5.88% Gross Profit is A$0.00 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's gross profit for the six months ended in Dec. 2025 was A$0.00 Mil. Bio-Gene Technology's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Bio-Gene Technology's gross profit for the six months ended in Dec. 2025 was A$0.00 Mil. Bio-Gene Technology's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Bio-Gene Technology's Gross Margin % for the quarter that ended in Dec. 2025 was N/A%.

Bio-Gene Technology had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


Bio-Gene Technology  (ASX:BGT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bio-Gene Technology had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


Bio-Gene Technology Gross Profit Related Terms


Bio-Gene Technology Gross Profit Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Gross Profit Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Gross Profit
Get a 7-Day Free Trial 0.57 0.88 0.60 0.00 0.00

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 0.00 0.00 0.00

ASX:BGT vs VRTX, REGN, MRNA: Gross Profit Comparison

For the Biotechnology subindustry, Bio-Gene Technology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Gene Technology Gross Profit vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Gross Profit distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's Gross Profit falls into.



Bio-Gene Technology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Bio-Gene Technology's Gross Profit for the fiscal year that ended in Jun. 2025 is calculated as

Gross Profit (A: Jun. 2025 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Bio-Gene Technology's Gross Profit for the quarter that ended in Dec. 2025 is calculated as

Gross Profit (Q: Dec. 2025 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Bio-Gene Technology's Gross Margin % for the quarter that ended in Dec. 2025 is calculated as

Gross Margin % (Q: Dec. 2025 )=Gross Profit (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Profit →
What does a Gross Profit of A$0.00 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Gross Profit of A$0.00 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Gross Profit too high?
Bio-Gene Technology's current Gross Profit is A$0.00 Mil.
How does Bio-Gene Technology's Gross Profit compare to VRTX and REGN?
Bio-Gene Technology's Gross Profit of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Gross Profit is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Gross Profit of A$0.00 Mil. The current Gross Profit is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Gross Profit is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.